Moltek Sağlık Hizmetleri Üretim ve Pazarlama A.Ş., established in 2007, has positioned itself as a pioneer in the Turkish nuclear medicine market. Known for its commitment to quality, Moltek employs advanced technologies and expert personnel, striving to become a leading global brand.
The company's core focus lies in manufacturing radiopharmaceuticals that adhere to international standards for both diagnosis and treatment. Through its adherence to Good Manufacturing Practice (GMP), Moltek ensures its products meet high safety and quality standards, catering to an expanding market's demands.
With its headquarters in Turkey, Moltek operates within the IT, Manufacturing, and Pharmaceutical industries. Their most recent financial milestone was a Seed Round investment on 14 July 2021, backed by Taxim Capital. This investment positions Moltek to enhance its global footprint and solidify its market share.